Search

Displaying results 4781 - 4790 of 10000 in total
  1. Drug

    Nisoldipine

    go.drugbank.com/drugs/DB00401
    Approved

    Nisoldipine may be used in alone or in combination with other agents in the management of hypertension. … Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.

  2. Drug

    TG-100801

    go.drugbank.com/drugs/DB05075
    Investigational

    It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological … TG100801 is a topically applied kinase inhibitor in macular degeneration patients.

  3. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. … TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B

  4. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006.

  5. Drug

    RAV12

    go.drugbank.com/drugs/DB05140
    Investigational

    RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. … RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid.

  6. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388]. … The drug made it to phase III trials before abandoned due to increased stroke.

  7. Drug

    Glembatumumab vedotin

    go.drugbank.com/drugs/DB05996
    Investigational

    A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  8. Target

    Solute carrier family 52, riboflavin transporter, member 2

    go.drugbank.com/bio_entities/BE0004841
    TargetTransporterHumans

    May also act as a receptor for 4-hydroxybutyrate (Probable)

    Synonyms: PERV-A receptor 1, Porcine endogenous retrovirus A receptor 1Function: 4-hydroxybutyrate receptor activity
  9. Drug

    Gataparsen

    go.drugbank.com/drugs/DB05141
    Investigational

    LY2181308 is an anti-sense oligonucleotide that potently downregulated survivin expression in human cancer cells derived from lung, colon, breast, prostate, ovary, cervix, skin and brain. … LY2181308 is known to target baculoviral IAP repeat-containing protein 5.

  10. Drug

    Doxercalciferol

    go.drugbank.com/drugs/DB06410
    ApprovedInvestigational

    Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients … Doxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc.